144 related articles for article (PubMed ID: 11377507)
1. New immunosuppressants in BMT/GVHD.
Basara N; Günzelmann S; Willenbacher W; Fauser AA; Kiehl MG
Transplant Proc; 2001 May; 33(3):2220-2. PubMed ID: 11377507
[No Abstract] [Full Text] [Related]
2. Can antibody prophylaxis allow sparing of other immunosuppressives?
Vincenti F; Grinyo J; Ramos E; Nashan B; Stuart F; Kuypers D; Brattstrom C; Cho S; Ekberg H; Johnson R
Transplant Proc; 1999; 31(1-2):1246-8. PubMed ID: 10083557
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient.
Basara N; Blau WI; Kiehl MG; Römer E; Rudolphi M; Bischoff M; Kirsten D; Sanchez H; Günzelmann S; Fauser AA
Transplant Proc; 1998 Dec; 30(8):4087-9. PubMed ID: 9865306
[No Abstract] [Full Text] [Related]
4. Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients.
Figueras J; Bernardos A; Prieto M; Gómez M; Rimola A; Ortiz de Urbina J; Cuervas-Mons V; de la Mata M; Dominguez-Granados R
Transplant Proc; 2002 Aug; 34(5):1511-3. PubMed ID: 12176461
[No Abstract] [Full Text] [Related]
5. Induction therapy for clinical intestinal transplantation: comparison of four different regimens.
Pinna AD; Weppler D; Nery JR; Khan F; Ruiz P; Kato T; De Faria W; Berho M; Tzakis AG
Transplant Proc; 2000 Sep; 32(6):1193-4. PubMed ID: 10995902
[No Abstract] [Full Text] [Related]
6. Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut.
Rodriguez V; Anderson PM; Trotz BA; Arndt CA; Allen JA; Khan SP
Pediatr Blood Cancer; 2007 Aug; 49(2):212-5. PubMed ID: 16261610
[TBL] [Abstract][Full Text] [Related]
7. Novel pharmacotherapeutic approaches to prevention and treatment of GVHD.
Jacobsohn DA; Vogelsang GB
Drugs; 2002; 62(6):879-89. PubMed ID: 11929336
[TBL] [Abstract][Full Text] [Related]
8. Daclizumab to prevent rejection after cardiac transplantation.
Hershberger RE; Starling RC; Eisen HJ; Bergh CH; Kormos RL; Love RB; Van Bakel A; Gordon RD; Popat R; Cockey L; Mamelok RD
N Engl J Med; 2005 Jun; 352(26):2705-13. PubMed ID: 15987919
[TBL] [Abstract][Full Text] [Related]
9. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
[TBL] [Abstract][Full Text] [Related]
10. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab.
Willenbacher W; Basara N; Blau IW; Fauser AA; Kiehl MG
Br J Haematol; 2001 Mar; 112(3):820-3. PubMed ID: 11260089
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience.
Basara N; Kiehl MG; Blau W; Römer E; Bischoff M; Schmetzer B; Kirsten D; Günzelmann S; Fauser AA
Transplant Proc; 2001 May; 33(3):2121-3. PubMed ID: 11377471
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
Ciancio G; Burke GW; Suzart K; Vaidya A; Roth D; Kupin W; Mattiazzi A; Rosen A; Esquenazi V; Miller J
Transplant Proc; 2003 Mar; 35(2):873-4. PubMed ID: 12644172
[No Abstract] [Full Text] [Related]
13. Is complete avoidance of calcineurin inhibitors or steroids now possible? Importance of patient selection and choice of regimen.
Vincenti F
Transplant Proc; 2001 Jun; 33(4 Suppl):11S-18S. PubMed ID: 11406263
[No Abstract] [Full Text] [Related]
14. Steroid-refractory graft-vs.-host disease: past, present and future.
Carpenter PA; Sanders JE
Pediatr Transplant; 2003; 7 Suppl 3():19-31. PubMed ID: 12603689
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
Burke GW; Ciancio C; Blomberg BB; Rosen A; Suzart K; Roth D; Kupin W; Esquenazi V; Miller J
Transplant Proc; 2002 Aug; 34(5):1610-1. PubMed ID: 12176505
[No Abstract] [Full Text] [Related]
16. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.
Srinivasan R; Chakrabarti S; Walsh T; Igarashi T; Takahashi Y; Kleiner D; Donohue T; Shalabi R; Carvallo C; Barrett AJ; Geller N; Childs R
Br J Haematol; 2004 Mar; 124(6):777-86. PubMed ID: 15009066
[TBL] [Abstract][Full Text] [Related]
17. Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients.
Elimelakh M; Dayton V; Park KS; Gruessner AC; Sutherland D; Howe RB; Reding MT; Eastlund T; van Burik JA; Singleton TP; Gruessner RW; Key NS
Haematologica; 2007 Aug; 92(8):1029-36. PubMed ID: 17640860
[TBL] [Abstract][Full Text] [Related]
18. The role of newer monoclonal antibodies in renal transplantation.
Vincenti F
Transplant Proc; 2001; 33(1-2):1000-1. PubMed ID: 11267163
[No Abstract] [Full Text] [Related]
19. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease.
Przepiorka D; Kernan NA; Ippoliti C; Papadopoulos EB; Giralt S; Khouri I; Lu JG; Gajewski J; Durett A; Cleary K; Champlin R; Andersson BS; Light S
Blood; 2000 Jan; 95(1):83-9. PubMed ID: 10607689
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2R antagonists in the prevention of acute rejection in living donor transplantation.
Ivanovski N; Popov Z; Kolevski P; Cakalaroski K; Spasovski G; Sikole A; Paneva-Masin J
Transplant Proc; 2001; 33(7-8):3203-4. PubMed ID: 11750374
[No Abstract] [Full Text] [Related]
[Next] [New Search]
